KPTI - Karyopharm Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
981.41M
Enterprise Value 3
803.16M
Trailing P/E
N/A
Forward P/E 1
-8.36
PEG Ratio (5 yr expected) 1
0.16
Price/Sales (ttm)
42.66
Price/Book (mrq)
16.37
Enterprise Value/Revenue 3
34.92
Enterprise Value/EBITDA 6
-3.96

Trading Information

Stock Price History

Beta (3Y Monthly) 2.40
52-Week Change 339.59%
S&P500 52-Week Change 313.42%
52 Week High 315.78
52 Week Low 33.92
50-Day Moving Average 311.62
200-Day Moving Average 38.56

Share Statistics

Avg Vol (3 month) 31.6M
Avg Vol (10 day) 31.69M
Shares Outstanding 562.79M
Float 37.81M
% Held by Insiders 118.45%
% Held by Institutions 192.99%
Shares Short (Oct 31, 2019) 410.69M
Short Ratio (Oct 31, 2019) 48.22
Short % of Float (Oct 31, 2019) 421.80%
Short % of Shares Outstanding (Oct 31, 2019) 417.02%
Shares Short (prior month Sep 30, 2019) 414.28M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-884.51%

Management Effectiveness

Return on Assets (ttm)-49.12%
Return on Equity (ttm)-181.13%

Income Statement

Revenue (ttm)23M
Revenue Per Share (ttm)0.38
Quarterly Revenue Growth (yoy)5,401.70%
Gross Profit (ttm)-131.04M
EBITDA -202.54M
Net Income Avi to Common (ttm)-209.15M
Diluted EPS (ttm)-3.42
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)267.53M
Total Cash Per Share (mrq)4.26
Total Debt (mrq)123.19M
Total Debt/Equity (mrq)205.76
Current Ratio (mrq)7.16
Book Value Per Share (mrq)0.95

Cash Flow Statement

Operating Cash Flow (ttm)-199.5M
Levered Free Cash Flow (ttm)-124.92M